Results 81 to 90 of about 4,771 (191)

Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts

open access: yes, 2009
Belinostat is a hydroxamate-type histone deactylase inhibitor (HDACi), which has recently entered phase I and II clinical trials. Microarray-based analysis of belinostat-treated cell lines showed an impact on genes associated with the G2/M phase of the ...
Pezzoli, P.   +8 more
core   +1 more source

Complete hematologic response in a patient with multiple pretreated angioimmunoblastic T‐cell lymphoma after belinostat therapy followed by allogeneic stem cell transplantation: A case report

open access: yesClinical Case Reports
Key Clinical Message Belinostat therapy followed by hematopoietic stem cell transplantation is a promising salvage strategy for heavily pretreated patients with peripheral T‐cell lymphoma.
Sigrid De Wilde, Carlos Graux
doaj   +1 more source

Tratamiento del cáncer basado en la epigenética

open access: yesCorreo Científico Médico, 2021
El cáncer es una enfermedad multifactorial que involucra a factores genéticos,  epigenéticos y ambientales en una compleja y no bien comprendida interrelación.
Yarimi Rodríguez Moldón   +3 more
doaj   +2 more sources

hiết kế, tổng hợp và đánh giá khả năng ức chế enzyme histone deacetylase (HDAC) in silico của một số dẫn xuất tương tự belinostat

open access: yesTạp chí Khoa học Đại học Cần Thơ, 2020
Belinostat là thuốc có khả năng ức chế enzyme HDAC khá tốt, được sử dụng điều trị các khối u ác tính về huyết học và khối u rắn. Trong nghiên cứu này, các dẫn xuất tương tự belinostat đã được tổng hợp thành công qua quy trình đơn giản và hiệu quả, phù ...
Nguyễn Cường Quốc   +12 more
doaj  

Supplementary Figures S1-S2 from Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia Cells

open access: yes, 2008
Supplementary Figures S1-S2 from Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia ...
Lora B. Kramer (14910317)   +5 more
core   +1 more source

Histone Deacetylase Inhibitors Are Protective in Acute but Not in Chronic Models of Ototoxicity

open access: yesFrontiers in Cellular Neuroscience, 2017
Previous studies have reported that modification of histones alters aminoglycoside-induced hair cell death and hearing loss. In this study, we investigated three FDA-approved histone deacetylase (HDAC) inhibitors (vorinostat/SAHA, belinostat, and ...
Chao-Hui Yang   +6 more
doaj   +1 more source

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates

open access: yes, 2008
PURPOSE: Histone deacetylases (HDAC) are involved in the regulation of gene transcription. Aberrant HDAC activity has been associated with tumorigenesis, and, therefore, HDACs are potential targets for the treatment of cancers, including tumors of the ...
Warren, K.E.   +6 more
core   +1 more source

Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome

open access: yesFrontiers in Medicine, 2019
Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma. The majority of MF cases present with only patches and plaques and the lesions are usually limited to the skin.
Tomonori Oka, Tomomitsu Miyagaki
doaj   +1 more source

Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

open access: yesOncoTargets and Therapy, 2014
The peripheral T-cell lymphomas are a rare and heterogeneous group of mature T-cell lymphomas with limited available therapies. The outcome of frontline chemotherapy regimens has been disappointing, with a long-term survival of only 20%-30%. There is an urgent need to optimize induction therapy by incorporating novel agents that target the dysregulated
Bodiford,Andrew   +3 more
openaire   +4 more sources

Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice

open access: yes, 2011
Copyright information:Taken from "The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo"http://www.translational-medicine.com/content/5/1/49Journal of Translational Medicine 2007;5():49-49 ...
Joanne Yoon (37162)   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy